{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:54:57Z","timestamp":1781909697830,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.path.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T02:04:32Z","timestamp":1731981872000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Classification of Urothelial Carcinoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Jie-Fu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.path.2018.07.011","article-title":"Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants","volume":"11","author":"Al-Ahmadie","year":"2018","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cll.2023.08.010","article-title":"Molecular pathology of urothelial carcinoma","volume":"44","author":"Al-Ahmadie","year":"2024","journal-title":"Clin Lab Med"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.path.2022.07.004","article-title":"Molecular taxonomy and immune checkpoint therapy in bladder cancer","volume":"15","author":"Guo","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.path.2024.09.003_bib6","series-title":"WHO classification of tumours","first-page":"150","article-title":"Invasive urothelial carcinoma","author":"Williamson","year":"2022"},{"issue":"3","key":"10.1016\/j.path.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.path.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat Genet"},{"issue":"7457","key":"10.1016\/j.path.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.path.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.3557","article-title":"Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors","volume":"48","author":"Kim","year":"2016","journal-title":"Nat Genet"},{"issue":"7793","key":"10.1016\/j.path.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.molcel.2020.05.012","article-title":"POLE mutation spectra are shaped by the mutant allele identity, its abundance, and mismatch repair status","volume":"78","author":"Hodel","year":"2020","journal-title":"Mol Cell"},{"issue":"7492","key":"10.1016\/j.path.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation Sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma","volume":"5","author":"Isharwal","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"6225","key":"10.1016\/j.path.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1260200","article-title":"TERT promoter mutations and telomerase reactivation in urothelial cancer","volume":"347","author":"Borah","year":"2015","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.path.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.anndiagpath.2015.06.007","article-title":"Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder","volume":"19","author":"Vail","year":"2015","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAS.0000000000000305","article-title":"Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation","volume":"39","author":"Zhong","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/his.13318","article-title":"Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma","volume":"72","author":"Brown","year":"2018","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/his.13441","article-title":"Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential","volume":"72","author":"Wang","year":"2018","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.path.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/path.5261","article-title":"Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder","volume":"248","author":"Isharwal","year":"2019","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41379-020-0453-z","article-title":"PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates","volume":"33","author":"Taylor","year":"2020","journal-title":"Mod Pathol"},{"issue":"13","key":"10.1016\/j.path.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","article-title":"Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma","volume":"23","author":"Catto","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1464-410X.2005.05671.x","article-title":"Microsatellite instability and transitional cell carcinoma of the upper urinary tract","volume":"96","author":"Roupret","year":"2005","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.path.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.path.2024.09.003_bib35","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.path.2024.09.003_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"23","key":"10.1016\/j.path.2024.09.003_bib37","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/cncr.30219","article-title":"Genomic characterization of response to chemoradiation in urothelial bladder cancer","volume":"122","author":"Desai","year":"2016","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.path.2024.09.003_bib38","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.path.2024.09.003_bib39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.22.00405","article-title":"A\u00a0randomized, double-blind, biomarker-selected, Phase II clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma","volume":"41","author":"Crabb","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.path.2024.09.003_bib41","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.path.2024.09.003_bib43","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.09.003_bib44","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"7691","key":"10.1016\/j.path.2024.09.003_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.path.2024.09.003_bib46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.path.2024.09.003_bib48","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.path.2024.09.003_bib49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.path.2024.09.003_bib50","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.path.2024.09.003_bib51","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.22.02144","article-title":"Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade","volume":"41","author":"Sarfaty","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.09.003_bib52","doi-asserted-by":"crossref","first-page":"e2200121","DOI":"10.1200\/PO.22.00121","article-title":"Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma","volume":"6","author":"Graf","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.path.2024.09.003_bib53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.path.2024.09.003_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2024.42.4_suppl.536","article-title":"Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma","volume":"42","author":"Alam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib57","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/PAS.0000000000002053","article-title":"International society of urological pathology consensus conference on current issues in bladder cancer. working group 4: molecular subtypes of bladder cancer-principles of classification and emerging clinical utility","volume":"48","author":"Warrick","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A\u00a0consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.path.2024.09.003_bib60","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"244","key":"10.1016\/j.path.2024.09.003_bib63","doi-asserted-by":"crossref","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.path.2024.09.003_bib64","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome","volume":"70","author":"Lindgren","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder cancer molecular taxonomy: summary from a consensus meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-020-02951-0","article-title":"A\u00a0four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases","volume":"478","author":"Bontoux","year":"2021","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.path.2024.09.003_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.path.2021.05.005","article-title":"Molecular pathology of urothelial carcinoma","volume":"14","author":"Al-Ahmadie","year":"2021","journal-title":"Surg Pathol Clin."},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib69","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1038\/s41467-022-34251-3","article-title":"FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation","volume":"13","author":"Warrick","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.eururo.2018.06.047","article-title":"Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications","volume":"74","author":"Hovelson","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.path.2024.09.003_bib71","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41379-018-0096-5","article-title":"Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases","volume":"31","author":"Sj\u00f6dahl","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.09.003_bib72","article-title":"The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges","author":"Mohanty","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.09.003_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health organization classification of tumors of the urinary system and male genital organs-Part B: Prostate and urinary tract tumors","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib74","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2024.09.003_bib75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib76","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib77","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A\u00a0molecular pathologic framework for risk stratification of stage t1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.path.2024.09.003_bib78","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cjp2.245","article-title":"Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer","volume":"8","author":"Jackson","year":"2022","journal-title":"J\u00a0Pathol Clin Res"},{"key":"10.1016\/j.path.2024.09.003_bib79","doi-asserted-by":"crossref","first-page":"875142","DOI":"10.3389\/fmed.2022.875142","article-title":"CK5\/6 and GATA3 defined phenotypes of muscle-invasive bladder cancer: impact in adjuvant chemotherapy and molecular subtyping of negative cases","volume":"9","author":"Koll","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.path.2024.09.003_bib80","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euros.2023.09.003","article-title":"Feasibility and impact of immunohistochemistry-based molecular subtyping for muscle-invasive bladder cancer in patients treated with radiation-based therapy","volume":"57","author":"Hesswani","year":"2023","journal-title":"Eur Urol Open Sci."},{"issue":"4","key":"10.1016\/j.path.2024.09.003_bib81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.path.2024.09.003_bib82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2020.07.006","article-title":"Invasive plasmacytoid urothelial carcinoma: a comparative study of E-cadherin and P120 catenin","volume":"102","author":"Sangoi","year":"2020","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.path.2024.09.003_bib83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A\u00a0high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.path.2024.09.003_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.09.003_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","article-title":"High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins","volume":"7","author":"Zheng","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"10.1016\/j.path.2024.09.003_bib87","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.path.2024.09.003_bib88","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/PAP.0000000000000433","article-title":"Updates on urinary bladder tumors with neuroendocrine features","volume":"31","author":"Akbulut","year":"2024","journal-title":"Adv Anat Pathol"},{"issue":"8","key":"10.1016\/j.path.2024.09.003_bib89","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2017.33","article-title":"Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma","volume":"30","author":"Roy","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.09.003_bib90","doi-asserted-by":"crossref","first-page":"e2100392","DOI":"10.1200\/PO.21.00392","article-title":"Clinical and genomic characterization of bladder carcinomas with glandular phenotype","volume":"6","author":"Almassi","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib91","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.path.2024.09.003_bib92","doi-asserted-by":"crossref","first-page":"573 e19","DOI":"10.1016\/j.urolonc.2019.06.021","article-title":"Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer","volume":"37","author":"Genitsch","year":"2019","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.path.2024.09.003_bib93","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.path.2024.09.003_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"269","key":"10.1016\/j.path.2024.09.003_bib95","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.path.2024.09.003_bib96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:31:15Z","timestamp":1760074275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918124000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1875918124000643"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2024.09.003","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Classification of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}